IL2 and chronic graft versus host disease: Based on the theory that Tregs preferentially respond to low-dose IL-2, we conducted a phase 1 trial of administering low-dose IL-2 therapy daily in patients with steroid-refractory chronic GVHD (SR-cGVHD).